寡免疫复合物型毛细血管内增生性肾小球肾炎伴肾小球M2巨噬细胞浸润
肾小球内以CD68+CD163+ M2巨噬细胞浸润为主,伴TGF-β广泛表达,尿可溶性CD163升高并与肾小球M2巨噬细胞数相关。中位随访16.4个月的11例中,5例完全缓解、2例部分缓解、1例肾功能稳定、3例进展。
要点
- 寡免疫复合物型毛细血管内增生性GN以肾小球M2巨噬细胞异常活化及CD8+ T细胞浸润为特征。
- 尿可溶性CD163/尿肌酐升高与肾小球CD68+CD163+巨噬细胞数相关,或为无创标志物。
- 糖皮质激素可能对该病有潜在治疗获益,整体预后一般较好。
核心结论
- Pauci-I-EPGN是一种罕见独立疾病实体,特征为肾小球内M2巨噬细胞异常活化、CD8+ T细胞浸润及TGF-β过表达驱动的炎症-纤维化失衡。
- 糖皮质激素可能提供潜在治疗获益,该队列总体结局一般较好。
主要发现
- 中位24小时尿蛋白2.00 g/d(0.30-7.77 g/d),中位血清肌酐1.14 mg/dL(0.54-5.36 mg/dL),7例有前驱感染。
- 光镜示肾小球毛细血管内增生性病变;免疫荧光IgG、IgA、IgM、C3、C1q及轻链均阴性;电镜未见电子致密物沉积。
- 免疫组化示肾小球炎症细胞主要为CD68+细胞及少量CD3+细胞;多重免疫荧光示CD68+CD163+细胞为主要浸润细胞类型,肾小球内见广泛TGF-β表达。
- 12例尿可溶性CD163/尿肌酐升高,且与肾小球CD68+CD163+巨噬细胞数相关。
- 11例中位随访16.4个月(0.6-80.5个月),5例完全缓解、2例部分缓解、1例肾功能稳定、3例进展(1例进展至终末期肾病)。
临床怎么用
- 对活检示毛细血管内增生性GN且免疫荧光阴性的患者,应警惕Pauci-I-EPGN,并评估肾小球M2巨噬细胞浸润。
- 尿可溶性CD163/尿肌酐或可作为反映肾小球CD68+CD163+巨噬细胞负荷的无创指标。
- 糖皮质激素可能为潜在治疗选择,但需结合个体情况谨慎评估。
局限性
- 未设对照组,糖皮质激素疗效无法确立因果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Pauci-immune endocapillary proliferative glomerulonephritis (GN) (Pauci-I-EPGN) is a rare glomerular disease with a heterogeneous and poorly understood etiology. Here we describe the clinicopathological features, immune cell infiltration patterns, and treatment outcomes of Pauci-I-EPGN. METHODS: Fifteen patients with biopsy-proven Pauci-I-EPGN, diagnosed between January 2012 and June 2025, were studied retrospectively. RESULTS: Fifteen patients (7 males and 8 females) aged 50.1 ±13.0 years at renal biopsy were included. The median 24 hour urine protein was 2.00 g/d (0.30-7.77 g/d), with a median serum creatinine level of 1.14 mg/dL (0.54-5.36 mg/dL). Seven cases had prodromal infection. Light microscopy (LM) showed endocapillary proliferative lesions in glomeruli. Immunofluorescence (IF) staining was negative for IgG, IgA, IgM, component C3, component C1q, and light chains. Electron microscopy (EM) revealed no electron-dense deposits. Immunohistochemical staining showed that inflammatory cells in glomeruli were mainly cluster of differentiation CD68+ cells and a small number of CD3+ cells. Multiplex IF staining demonstrated that CD68+ CD163+ cells were the predominant infiltrating cell type in glomeruli. Extensive transforming growth factor-beta (TGF-β) expression was observed within glomeruli. Besides, urinary soluble CD163 levels normalized to urinary creatinine (u-Cr) were elevated in 12 patients and correlated with the number of glomerular CD68+ CD163+ macrophages. Among 11 patients with a median follow-up period of 16.4 months (0.6-80.5 months), 5 achieved complete remission, 2 achieved partial remission, 1 showed stable kidney function, and 3 had progressive renal disease (1 progressed to end-stage renal disease [ESRD]). CONCLUSION: Pauci-I-EPGN is a rare distinct entity characterized by abnormal activation of intraglomerular M2 macrophages and CD8+ T cell infiltration, with inflammation-fibrosis imbalance driven by TGF-β overexpression. Corticosteroids may offer a potential therapeutic benefit for this type of disease. The overall outcomes in this cohort were generally favorable.
引用
- Ma L, Kang M, Qiao Z, et al. Pauci-Immune Endocapillary Proliferative Glomerulonephritis With Glomerular M2 Macrophage Infiltration. Kidney Int Rep. 2026. PMID: 41732756. doi:10.1016/j.ekir.2026.103791
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。